Janssen Pharmaceutical Companies: CHMP Recommends Amivantamab in Combination With Lazertinib for the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
November 16, 2024
November 16, 2024
NEW BRUNSWICK, New Jersey, Nov. 16 (TNSres) -- Janssen Pharmaceutical Companies, a subsidiary of Johnson and Johnson, issued the following news release:
* * *
The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients with advanced NSCLC with EGFR ex19del or L858R substitution mutations/1
In the Phase 3 MARIPOSA study, amivantamab plus lazertinib significantly reduced risk of . . .
* * *
The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients with advanced NSCLC with EGFR ex19del or L858R substitution mutations/1
In the Phase 3 MARIPOSA study, amivantamab plus lazertinib significantly reduced risk of . . .